Entrada Therapeutics, Inc. Common Stock
TRDA Real Time Price USDRecent trades of TRDA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by TRDA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy May. 21, 2024
-
Patent Title: Cell penetrating peptides and methods of making and using thereof Jan. 18, 2022
-
Patent Title: Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy Nov. 09, 2021
-
Patent Title: Cell penetrating peptides and methods of making and using thereof Oct. 27, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of TRDA in WallStreetBets Daily Discussion
Recent insights relating to TRDA
Recent picks made for TRDA stock on CNBC
ETFs with the largest estimated holdings in TRDA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TRDA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.